Smith Shellnut Wilson’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $767K | Sell |
3,049
-292
| -9% | -$62.8K | 0.29% | 63 |
|
|
2026
Q1 | $727K | Sell |
3,341
-1,086
| -25% | -$241K | 0.32% | 62 |
|
|
2025
Q4 | $1.01M | Hold |
4,427
| – | – | 0.39% | 53 |
|
|
2025
Q3 | $1.03M | Buy |
4,427
+698
| +19% | +$142K | 0.39% | 51 |
|
|
2025
Q2 | $692K | Sell |
3,729
-845
| -18% | -$157K | 0.3% | 59 |
|
|
2025
Q1 | $958K | Buy |
4,574
+54
| +1% | +$10.5K | 0.44% | 50 |
|
|
2024
Q4 | $803K | Buy |
4,520
+245
| +6% | +$45K | 0.36% | 53 |
|
|
2024
Q3 | $844K | Sell |
4,275
-12
| -0.3% | -$2.24K | 0.38% | 49 |
|
|
2024
Q2 | $735K | Hold |
4,287
| – | – | 0.36% | 49 |
|
|
2024
Q1 | $781K | Sell |
4,287
-187
| -4% | -$32.2K | 0.41% | 45 |
|
|
2023
Q4 | $693K | Sell |
4,474
-38
| -0.8% | -$5.54K | 0.4% | 47 |
|
|
2023
Q3 | $673K | Hold |
4,512
| – | – | 0.41% | 41 |
|
|
2023
Q2 | $608K | Sell |
4,512
-20
| -0.4% | -$2.93K | 0.34% | 54 |
|
|
2023
Q1 | $722K | Hold |
4,532
| – | – | 0.44% | 41 |
|
|
2022
Q4 | $732K | Sell |
4,532
-154
| -3% | -$23.6K | 0.45% | 42 |
|
|
2022
Q3 | $629K | Buy |
4,686
+136
| +3% | +$19.5K | 0.42% | 45 |
|
|
2022
Q2 | $697K | Sell |
4,550
-64
| -1% | -$9.78K | 0.43% | 43 |
|
|
2022
Q1 | $748K | Buy |
4,614
+4
| +0.1% | +$581 | 0.39% | 46 |
|
|
2021
Q4 | $624K | Buy |
4,610
+122
| +3% | +$14.4K | 0.31% | 60 |
|
|
2021
Q3 | $484K | Sell |
4,488
-998
| -18% | -$114K | 0.28% | 69 |
|
|
2021
Q2 | $618K | Hold |
5,486
| – | – | 0.36% | 57 |
|
|
2021
Q1 | $594K | Sell |
5,486
-35
| -0.6% | -$3.74K | 0.36% | 53 |
|
|
2020
Q4 | $592K | Buy |
5,521
+660
| +14% | +$63.4K | 0.35% | 49 |
|
|
2020
Q3 | $426K | Sell |
4,861
-725
| -13% | -$68.3K | 0.16% | 69 |
|
|
2020
Q2 | $548K | Sell |
5,586
-59
| -1% | -$5.2K | 0.39% | 48 |
|
|
2020
Q1 | $430K | Sell |
5,645
-1,102
| -16% | -$93.9K | 0.36% | 52 |
|
|
2019
Q4 | $597K | Buy |
6,747
+2,669
| +65% | +$222K | 0.4% | 51 |
|
|
2019
Q3 | $309K | Buy |
4,078
+514
| +14% | +$35.2K | 0.23% | 87 |
|
|
2019
Q2 | $259K | Buy |
3,564
+28
| +0.8% | +$2.2K | 0.19% | 101 |
|
|
2019
Q1 | $285K | Buy |
3,536
+29
| +0.8% | +$2.37K | 0.23% | 95 |
|
|
2018
Q4 | $323K | Sell |
3,507
-29
| -0.8% | -$2.55K | 0.35% | 57 |
|
|
2018
Q3 | $334K | Buy |
+3,536
| New | +$335K | 0.3% | 59 |
|
|
2018
Q1 | $347K | Sell |
3,662
-1,381
| -27% | -$152K | 0.3% | 53 |
|
|
2017
Q4 | $488K | Buy |
5,043
+125
| +3% | +$11.8K | 0.41% | 49 |
|
|
2017
Q3 | $437K | Buy |
+4,918
| New | +$374K | 0.38% | 54 |
|
Other funds holding ABBV
Smith Shellnut Wilson's ABBV Position: Q2 2026 in Review
Smith Shellnut Wilson reduced its AbbVie (ABBV) stake by 8.7% in Q2 2026, selling an estimated $62.8K and leaving 3,049 shares worth $767K. The position accounts for 0.29% of the portfolio, ranked #63.
Smith Shellnut Wilson first reported a position in ABBV in Q3 2017 and has held it in 35 quarters since. The position peaked at $1.03M in Q3 2025. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Smith Shellnut Wilson held 3,049 shares of AbbVie worth $767K as of Q2 2026.
- Smith Shellnut Wilson sold 292 AbbVie shares in Q2 2026, an estimated $62.8K.
- AbbVie made up 0.29% of Smith Shellnut Wilson's portfolio in Q2 2026, its #63 holding.
- Smith Shellnut Wilson first reported a position in AbbVie in Q3 2017 and has held it in 35 quarters since.
- Smith Shellnut Wilson's AbbVie position peaked at $1.03M in Q3 2025.
- 4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Smith Shellnut Wilson's 13F filing for Q2 2026, filed 3 Aug 2026.